Cynthia Dukes | VP, Drug Development Services and Global Head of Vaccine Center of Excellence
ICON Clinical Research

Cynthia Dukes, VP, Drug Development Services and Global Head of Vaccine Center of Excellence, ICON Clinical Research

Cynthia Dukes brings over 40 years of diversified clinical experience including 34 years of clinical research experience in General Medicine and Infectious Disease/Vaccines.

Cynthia began her clinical research experience as the Clinical Team Lead at Baylor College of Medicine’s Vaccine Treatment Evaluation Unit and  Influenza and Respiratory Disease Research Center where she gained valuable experience in general medicine, vaccine and infectious disease studies. Following this experience she spent 14 years in pharma gaining experience in infectious disease, vaccines, immunoglobulins, allergy, immunology and oncology including 10 years at Pasteur Merieux Connaught (now sanofi Pasteur).  During her 18 years in the CRO industry, Cynthia has been a significant contributor to the therapeutic areas of oncology, vaccines, infectious disease, general medicine, women’s health and rare disease. Whilst in pharma, Cynthia participated in more than 40 INDs leading to eight product approvals, including five vaccines, 2 oncology products and one immunoglobulin. While at ICON she founded ICON's Center of Excellence for Vaccines and Rare Disease and has provided strategic and management oversight on numerous studies across multiple therapeutic areas including pivotal studies leading to the approval of numerous drugs and vaccines (15).

In 2014, Cynthia was acknowledged as one of the Top 50 Influential People in Vaccine Development by a global Vaccine Nation Survey and a Top Leader within ICON. ICON was also recognized as “Best CRO” at the Vaccine Industry Excellence Award dinner at the World Vaccine Congress, April 2014 and 2017and runner up 2018. In 2015, Cindy was recognized as an ICON Top Leader at ICON and  as a Distinguished Alumni at Baylor College of Medicine and most recently in August of 2016, she was again recognized as one of the Top 100 leaders in the industry by PharmaVoice.


Plenary, April 7 @ 11:40


Seasonal vaccine studies: Critical success factors

Day 2, April 8 @ 12:10

Best Practices in Vaccine Study Execution

last published: 05/Mar/20 10:35 GMT

back to speakers

Sign Up for Event Updates